Unicycive Therapeutics (NASDAQ:UNCY) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research report on Friday, November 22nd. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $5.50.

Unicycive Therapeutics Trading Down 4.9 %

Unicycive Therapeutics stock opened at $0.74 on Wednesday. The firm has a market capitalization of $76.81 million, a P/E ratio of -0.76 and a beta of 2.30. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.82. The stock’s fifty day simple moving average is $0.65 and its 200-day simple moving average is $0.49.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC raised its stake in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after acquiring an additional 62,881 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Unicycive Therapeutics in the third quarter valued at approximately $29,000. Walleye Capital LLC purchased a new position in shares of Unicycive Therapeutics during the third quarter worth approximately $2,040,000. Acuta Capital Partners LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $807,000. Finally, Great Point Partners LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $3,491,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.